Changes of hip fracture in older patients before and after the COVID-19 pandemic: a retrospective multicentre study in Japan.

Publication date: Dec 06, 2024

The COVID-19 pandemic had a significant impact on healthcare systems and the general population. However, it remains unclear to what extent these major societal changes have had an impact on the management of hip fractures in older people in Japan. Therefore, we investigated the effect of the COVID-19 pandemic on the number of patients with hip fractures, their characteristics, and their perioperative management as a retrospective multicentre study. We included 1894 patients aged ≥ 65 years who underwent surgery for hip fracture at three hospitals between January 2019-December 2021. Patients were classified according to the time of injury; patients treated between January-December 2019, January-December 2020, and January-December 2021 were divided into the pre-COVID-19 group, early COVID-19 group, and late COVID-19 group, respectively. We compared age, sex, body mass index, preadmission residence, surgical procedure, length of hospital stay, waiting time for surgery, in-hospital complications, and in-hospital death. Our findings suggested that the early COVID-19 and late COVID-19 groups showed a 6. 8% and 7. 5% reduction in the number of HF patients, respectively, compared to the pre-COVID-19 group. Waiting days for surgery, length of hospital stay, and in-hospital mortality or complication rates did not significantly change before and after the pandemic. However, infection was increased in the early COVID-19 group regarding the subgroup of complications. The COVID-19 pandemic altered the characteristics of hip fractures in older individuals.

Open Access PDF

Concepts Keywords
Japan Aged
Pandemic Aged, 80 and over
Sex COVID-19
Surgery COVID-19
Female
Hip Fractures
Hip fractures
Hip injuries
Hospital Mortality
Humans
Japan
Length of Stay
Male
Pandemics
Postoperative Complications
Proximal femoral fractures
Retrospective Studies
SARS-CoV-2
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease MESH complications
disease MESH death
disease MESH infection
disease MESH Long Covid
pathway REACTOME Reproduction
disease MESH lifestyle
disease MESH depression
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Etoperidone
disease IDO intervention
disease MESH pressure ulcer
drug DRUGBANK Coenzyme M
disease MESH aspiration pneumonia
disease MESH urinary tract infections
drug DRUGBANK Iron
disease MESH tics
disease MESH thrombosis
disease MESH embolism
disease MESH Respiratory tract infection
drug DRUGBANK Methylergometrine
disease MESH comorbidity
disease MESH frailty
disease IDO country
disease MESH emergency
disease MESH misdiagnosis
disease MESH bacterial infections
drug DRUGBANK Methyl isocyanate
disease MESH Dementia
disease IDO virulence
disease MESH postoperative complications
disease MESH Sarcopenia
drug DRUGBANK Carboxyamidotriazole
drug DRUGBANK Caffeine
drug DRUGBANK Ibuprofen

Original Article

(Visited 4 times, 1 visits today)